C
CARsgen Therapeutics Tech Stack
CAR T-cell therapies for hematologic malignancies and solid tumors
CARsgen is a Shanghai-based biopharmaceutical company spanning 501–1,000 employees, operating integrated CAR T-cell development and manufacturing across China and the U.S. The hiring mix is sales-heavy (13 of 35 active roles) paired with substantial manufacturing and research teams, reflecting the operational maturity required to move from clinical development into commercial-scale cell therapy production. Active projects center on CAR-T center buildout, plasmid and manufacturing process optimization, and real-world evidence studies—indicating a company shifting focus toward operational scale and market access rather than pure discovery.
Tech Stack 11 technologies
What CARsgen Therapeutics Is Building
◆Challenges
- Patient selection and return rates
- Establishing car-t centers
- Streamlining technology project application
- Managing government affairs coordination
- Ensuring timely policy compliance
- Quality issue management
- Optimizing car-t manufacturing process
- Reducing gmp production issues
- Ensuring high patient screening rates
- Building kol relationships
▲Active Projects
- Car-t center establishment
- Plasmid production process development
- Building oncology academic exchange platform
- Supervising car-t center operations
- Academic outreach
- Technology project application
- Environmental risk mitigation program
- Real world evidence (rwe) studies
- Car-t cell manufacturing process development
- Cmc project full process management
Hiring Activity
35 roles · 25 in 30d
Department
Seniority
Company intelligence
